Original Publication Date: 1 January, 2015
Publication / Source: Clinical Investigation
Authors: Wei-Chen Lu, Chia-Chi Lin & James Chih-Hsin Yang
Angiogenesis is an essential component of tumor growth and metastasis. To date, an anti-VEGF antibody, bevacizumab, in combination with paclitaxel and carboplatin in the first-line setting is the only approved antiangiogenic treatment in non-small-cell lung cancer (NSCLC). Angiokinase inhibitors are oral small-molecule agents. They not only inhibit the VEGF pathway, but also target other important signaling pathways contributing to angiogenesis: the PDGF and FGF pathways.